English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 38.78%
Price change 2019 → 2020: 66.25%
Price change 2020 → 2021: 6.78%
Price change 2021 → 2022: 11.83%
Price change 2022 → 2023: -26.73%
Price change 2023 → 2024: -30.74%
Price change 2024 → 2025: 35.81%
Price change 2025 → 2026: 14.11%
Price change 2026 (year to date): 15.25%
Financial growth
Revenue CAGR (8 years): 3.54%
Earnings CAGR (8 years): -5.39%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 0.95
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 27.64
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 1.28% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Genmab A/S | 41.5 | 0.95 | +28.8 % | 🔒 |
| Illumina, Inc. | 42.4 | 0.94 | +11.0 % | – |
| ResMed Inc. | 20.4 | 0.14 | +10.8 % | ★ 5/5 |
| Koninklijke Philips N.V. | 17.6 | 0.74 | −2.3 % | – |
| Sartorius Stedim Biotech S.A. | 51.0 | 0.64 | +13.7 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by Genmab A/S over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2025 |
|---|---|
| Cash and investments | 1.7 bn |
| Total Debt | 5.5 bn |
| Net Debt | 3.8 bn |
| Equity | 5.8 bn |
| Total assets | 12.8 bn |
| Operating cash flow | 1.2 bn |
| Investments (capex) | 57.1 m |
| Free cash-flow | 1.2 bn |
| Share buybacks | 446 m |
| Dividends paid | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Dividends and earnings
Genmab A/S: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 06/08/2026 | 31.78 | 23.36 | +36.0 % |
| 07/05/2026 | 5.27 | 10.10 | -47.8 % |
| 17/02/2026 | 3.14 | 17.89 | -82.4 % |
| 06/11/2025 | 41.79 | 31.44 | +32.9 % |
| 07/08/2025 | 34.65 | 25.51 | +35.8 % |
| 08/05/2025 | 20.26 | 15.81 | +28.1 % |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.